Skip to content

Effectiveness and safety of combination whitening cream DEPIWHITE advance in melasma

Effectiveness and safety of combination whitening cream DEPIWHITE advance in melasma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230323001
Enrollment
36
Registered
2023-03-23
Start date
2021-02-28
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with melasma on both cheeks melasma, combination whitening cream, depiwhite

Interventions

18 patients were treated with Depiwhite cream
Apply cream depiwhite 2 times a day for 1 month then once a day for 3 months + depiwhtie sunscreen. Then they were followed up after stop for 6 months,18 patients were treated with Depiwhite cream
Apply cream 2% hydroquinone onces a day for 1 month then once per two days for 3 months + depiwhtie sunscreen. Then they were followed up after stop for 6 months
combination whitening cream DEPIWHITE,2% hydroquinone cream

Sponsors

P.&.O. HEALTH CARE CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60 years 2. Have melasma on both cheeks

Exclusion criteria

Exclusion criteria: 1. Patients having infection or active wound in the test area 2. Taking oral or topical whitening agents within 1 month or laser or melasma treatment within 6 months prior to inclusion 3. Allery to alpha-hydroxy acid, antipollon, phosphatase activators, vitamin PP, kojic acid, vitamin C, arbutin, luteoline and parsley 4. Pregnancy 5. Taking oral antioxidants

Design outcomes

Primary

MeasureTime frame
Melasma severity baseline, 1 month, 3 months, after stop treatment at 1 & 3 & 6 months mMASI score

Secondary

MeasureTime frame
Melanin index and Erythema Index baseline, 1 month, 3 months, after stop treatment at 1 & 3 & 6 months Mexameter,Physician assessment baseline, 1 month, 3 months, after stop treatment at 1 & 3 & 6 months Quatile scale,Patient Assessment baseline, 1 month, 3 months, after stop treatment at 1 & 3 & 6 months VAS,Safety baseline, 1 month, 3 months, after stop treatment at 1 & 3 & 6 months Adverse events

Countries

Thailand

Contacts

Public ContactSasima Eimpunth

Faculty of Medicine Siriraj Hospital, Mahidol University

doctorsasima@gmail.com0858303555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026